Published in Lancet Neurology today, is our complete description of the bexarotene trial. It is a mixture of good and bad news!

Sadly, we concluded that the drug has too many side-effects to take further as a treatment for people with MS. And the trial did not hit the “primary endpoint” that was pre-specified as a measure of “success”. However, there is clear evidence that bexarotene has a small effect to promote remyelination. The next step is to see if chemists can create a better drug. Bexarotene works on all the subtypes of the retiond X receptor, but the remyelinating action probably comes from the gamma subtype, whereas the alpha and beta subtype are responsible for the side effects.

You can read more here.